C-Path’s TRxA Announces $250,000 Grant for Drug Development Project on Antibiotic-Resistant Gram-Negative Bacteria

TUCSON, Ariz. August 13, 2024– Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today that Kenneth Keiler, Ph.D., Professor of Molecular Biosciences at the University of Texas at Austin, has been awarded a research grant for his innovative project titled “Inhibitors of the Gram-negative Cell Envelope Stress Response as Anti-Infectives and Antibiotics.” Continue reading

Flambeau Medical is Growing in Phoenix

Flambeau Medical, a full-service, contract manufacturing organization serving the medical device and life science industries is growing in Phoenix. The company provides a full suite of development and manufacturing capabilities in FDA registered and ISO-13485:2016 certified manufacturing operations.Continue reading

Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing (“AST”) directly from positive blood culture (“PBC”) bottles and bacterial isolated colonies (“Isolates”) to report accurate results within 4.5 hours, on average.Continue reading

C-Path’s TRxA Announces $250,000 Award for Drug Development Project in ALS

TUCSON, Ariz., August 8, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today a new research grant awarded to Daniela C. Zarnescu, Ph.D., Professor of Cellular and Molecular Physiology at Penn State University College of Medicine, in collaboration with Jon Njardarson, Ph.D., Professor at the University of Arizona. Continue reading

Anivive Receives NIAID Contract Worth Up to $33M to Progress Valley Fever Vaccine

LONG BEACH, Calif., Aug. 2, 2024 /PRNewswire/ – Anivive Lifesciences Inc, a One Health technology company today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded Anivive a new contract (#75N93024C00009) worth up to $33M to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.Continue reading